| A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma (NCT06566586) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2024-11-06 |
| Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR) (NCT06784791) | University Hospital, Essen | 2024-11-06 |
| Efficacy and Safety of VDPHL01 in Males With AGA (NCT06724614) | Veradermics, Inc. | 2024-11-06 |
| A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer (NCT06710288) | ImmunityBio, Inc. | 2024-11-06 |
| Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression (NCT06511908) | National Institute of Mental Health (NIMH) | 2024-11-06 |
| Subtyping Primary Aldosteronism With Para-chloro-2-[18F]Fluoroethyl-etomidate (NCT06616142) | University Medical Center Groningen | 2024-11-06 |
| Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer (NCT06479239) | University of Virginia | 2024-11-06 |
| Conversion Surgery Vs. Palliative Care in Pancreatic Cancer Oligometastatic to the Liver (NCT06690528) | Azienda Ospedaliera di Padova | 2024-11-06 |
| Efficacy and Safety of ENN0403 in Patients At High Risk for Acute Kidney Injury Following Elective Cardiac Surgery (NCT06632613) | EnnovaBio | 2024-11-05 |
| An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB (NCT06488924) | JCR Pharmaceuticals Co., Ltd. | 2024-11-05 |
| Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL (NCT06601504) | Hutchmed | 2024-11-05 |
| RHPRG4 FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE (NCT06520202) | Lubris Bio Pty Ltd | 2024-11-05 |
| Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants (NCT06647407) | Sanofi Pasteur, a Sanofi Company | 2024-11-05 |
| SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy (NCT06676722) | The First Affiliated Hospital of Xiamen University | 2024-11-05 |
| Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer (NCT06488222) | University of Florida | 2024-11-05 |
| Recovery Times of Half Dose Sugammadex and Neostigmine for Rocuronium-induced Neuromuscular Blockade (NCT06794450) | Universitas Padjadjaran | 2024-11-05 |
| High Heated Humidity in Stem Cell Transplant (NCT05358262) | AHS Cancer Control Alberta | 2024-11-05 |
| MT1013 Injection for the Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease (NCT06690242) | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | 2024-11-04 |
| CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors (NCT06735495) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2024-11-04 |
| A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1) (NCT06685692) | Aldeyra Therapeutics, Inc. | 2024-11-04 |
| Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC (NCT06643793) | Affiliated Hospital of Nantong University | 2024-11-04 |
| A Study to Test How Well BI 3720931 is Tolerated and Whether it Improves Lung Function in People With Cystic Fibrosis (Lenticlair™ 1) (NCT06515002) | Boehringer Ingelheim | 2024-11-04 |
| A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD (NCT06488313) | Arcturus Therapeutics, Inc. | 2024-11-04 |
| VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy (NCT05920343) | Ottawa Hospital Research Institute | 2024-11-04 |
| An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1). (NCT06634849) | Pathios Therapeutics Pty Ltd | 2024-11-04 |
| Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma (NCT06121180) | H. Lee Moffitt Cancer Center and Research Institute | 2024-11-04 |
| Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue (NCT06482515) | University of Maryland, Baltimore | 2024-11-04 |
| All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II Trial (NCT06636981) | Fudan University | 2024-11-04 |
| A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) (NCT06733935) | Nkarta, Inc. | 2024-11-04 |
| Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium (NCT06399679) | Washington University School of Medicine | 2024-11-04 |
| A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma (NCT06639347) | Shanghai Hengrui Pharmaceutical Co., Ltd. | 2024-11-04 |
| Complement Inhibition: Attacking the Overshooting Inflammation @Fter Subarachnoid Hemorrhage (CIAO@SAH) (NCT06359782) | Haaglanden Medical Centre | 2024-11-04 |
| Identifying Individuals at Risk of Glucocorticoid-Induced Impairment of Bone Disease (NCT06421597) | Odense University Hospital | 2024-11-04 |
| Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02) (NCT06596694) | Merck Sharp & Dohme LLC | 2024-11-03 |
| A Randomized Clinical Trial to Evaluate the Effectiveness of Oral Potassium Citrate in Preventing Ureteral Stent Encrustation in Patients Undergoing Ureteroscopy for Uric Acid Kidney Stones (NCT06819553) | Zagazig University | 2024-11-03 |
| Effectiveness and Safety of Zingiber Officinale Transdermal Patch for Acne Vulgaris; Study of Interleukin 1 and Skin Microbiome (NCT06787222) | Hasanuddin University | 2024-11-03 |
| A Multicenter, Single-arm, Open-label Study Evaluating the Safety and Efficacy of AK112 Combined With Chemotherapy as First-line Treatment for Non-squamous NSCLC Patients With BRAIN Metastases and Negative Driver Genes (IVO BRAIN) (NCT06684873) | Sun Yat-sen University | 2024-11-02 |
| Oral Intake of Mg in Controlled Asthmatic Patients (NCT06721247) | Zagazig University | 2024-11-02 |
| Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes (NCT06490913) | Fujian Cancer Hospital | 2024-11-01 |
| Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis (NCT06569147) | Dana-Farber Cancer Institute | 2024-11-01 |
| ExoFlo™ Infusion for Post-Acute COVID-19 and Chronic Post-COVID-19 Syndrome (NCT05116761) | Direct Biologics, LLC | 2024-11-01 |
| Efficacy and Safety of a Two-week Dosing Regimen of Vinorelbine Combined with Liposomal Doxorubicin in the Treatment of HER2-negative Advanced Breast Cancer (NCT06653972) | Wang Jiayu | 2024-11-01 |
| Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer (NCT06593548) | Fudan University | 2024-11-01 |
| RATT Vs. VATT for Early-stage TETs (NCT06654830) | Shanghai Zhongshan Hospital | 2024-11-01 |
| Acetylcholinesterase Inhibitor in Anorexia Nervosa: Multicenter, Double-Blind, Placebo-Controlled Trial (NCT06687993) | Centre Hospitalier St Anne | 2024-11-01 |
| Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission (NCT06669143) | Ruijin Hospital | 2024-11-01 |
| Sequential T and I With H101 Via HAI for BCLC C Stage HCC: A Prospective Single-Center Single-Arm Pilot Study (NCT06685354) | Henan Cancer Hospital | 2024-11-01 |
| Artificial Intelligence Driven Personalisation of Radiotherapy and Concomitant Androgen Deprivation Therapy for Prostate Cancer Patients (the HypoPro Trial) (NCT06772441) | German Oncology Center, Cyprus | 2024-11-01 |
| Adjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung Cancer (NCT06773156) | Second Affiliated Hospital of Nanchang University | 2024-11-01 |
| CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC (NCT06652412) | Fudan University | 2024-11-01 |
| NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma (NCT06651151) | Oslo University Hospital | 2024-11-01 |
| Trial of Reduced Alteplase Dose for Parapneumonic Effusion (TRAPPE) (NCT05766124) | Chinese University of Hong Kong | 2024-11-01 |
| Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases (NCT06702826) | Rongrong Zhou | 2024-11-01 |
| Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial） (NCT06647940) | Sun Yat-sen University | 2024-11-01 |
| Nintedanib Treatment in Unicentric Castleman Disease (NCT06643091) | Assistance Publique - Hôpitaux de Paris | 2024-11-01 |
| Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. (NCT06563999) | Sun Yat-sen University | 2024-11-01 |
| Evaluation of Gixam's Performance in a FIT Negative Population (NCT06612281) | Jubaan Ltd. | 2024-11-01 |
| Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma (NCT06684600) | Peking University | 2024-11-01 |
| Neoadjuvant Chemotherapy + PD-1 Inhibitor+Different Radiotherapy Fractionations for HR+/HER2- Breast Cancer (NCT06639672) | Lei Liu | 2024-11-01 |
| Rickettsia Clearance Study (NCT05972772) | Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit | 2024-11-01 |
| CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC (NCT06665087) | Fudan University | 2024-11-01 |
| A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS) (NCT06709417) | Shanghai Chest Hospital | 2024-11-01 |
| Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer (NCT06678230) | The First Hospital of Jilin University | 2024-11-01 |
| Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC (NCT06657690) | Sun Yat-sen University | 2024-11-01 |
| Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment (NCT06069843) | Icahn School of Medicine at Mount Sinai | 2024-11-01 |
| A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy (NCT06635772) | Hansoh BioMedical R&D Company | 2024-11-01 |
| Randomized Trial of Plasma ctDNA Methylation-Guided Adjuvant Therapy in T4N0 and Low-Risk Stage III Colorectal Cancer (NCT07562503) | Fudan University | 2024-11-01 |
| Effectiveness of Topical Vancomycin in Reducing Sternal Wound Infections Post-Cardiac Surgery (NCT06651268) | Liaquat National Hospital & Medical College | 2024-11-01 |
| Vebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC) (NCT06644313) | Shanghai Pulmonary Hospital, Shanghai, China | 2024-11-01 |
| Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer (NCT07562711) | Fudan University | 2024-11-01 |
| Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer (NCT06648200) | Shanghai Pulmonary Hospital, Shanghai, China | 2024-11-01 |
| Esophageal Replacement With a Decellularized Human Esophagus Graft (NCT06662370) | Assistance Publique - Hôpitaux de Paris | 2024-11-01 |
| Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic Anemia (NCT06695741) | Institute of Hematology & Blood Diseases Hospital, China | 2024-11-01 |
| Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer (NCT06575725) | City of Hope Medical Center | 2024-11-01 |
| NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study (NCT06650709) | British Columbia Cancer Agency | 2024-11-01 |
| Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC) (NCT06681285) | Hebei Medical University Fourth Hospital | 2024-11-01 |
| Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma (NCT06680115) | First Affiliated Hospital of Guangxi Medical University | 2024-11-01 |
| Zanubrutinib Combined With BEAM for ASCT in Relapsed and Refractory DLBCL (NCT06652165) | Ruijin Hospital | 2024-11-01 |
| Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer (NCT06826079) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2024-11-01 |
| Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia (NCT05638763) | Hospital Universitario Dr. Jose E. Gonzalez | 2024-11-01 |
| Induction of Remission in Autoimmune Hepatitis With Azathioprine vs. MMF (NCT06650124) | Institute of Liver and Biliary Sciences, India | 2024-11-01 |
| Deucravacitinib Rosacea (NCT06532136) | Icahn School of Medicine at Mount Sinai | 2024-11-01 |
| Supplemental Postoperative Bupivacaine Following Non-Surgical Endodontic Treatment (NCT06655454) | New York University | 2024-11-01 |
| Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALL (NCT06658925) | Institute of Hematology & Blood Diseases Hospital, China | 2024-11-01 |
| Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells (NCT05017298) | Celltex Therapeutics Corporation | 2024-11-01 |
| Phase 3 Lot Consistency Study of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine (NCT06485752) | Novavax | 2024-11-01 |
| Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC (NCT06500208) | Shanghai Jiao Tong University School of Medicine | 2024-11-01 |
| Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM (NCT06518551) | Omar Nadeem, MD | 2024-11-01 |
| Role of Dexmedetomidine as Synergistic Agent (NCT06662175) | Lady Reading Hospital, Pakistan | 2024-11-01 |
| Investigating the Cholinergic Contribution to Gait Dysfunction in Parkinson's Disease (NCT06903910) | University of Virginia | 2024-11-01 |
| Neuromodulation of the Hippocampus to Reduce Intrusive Re-Experiencing in PTSD: A Randomized Controlled Trial (NCT06639061) | Tel Aviv University | 2024-11-01 |
| Trial Investigating the Safety and Efficacy of BRC-003 in Refractory Post-Traumatic Epilepsy (NCT06523725) | Dr. Paul Lyons | 2024-11-01 |
| Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC Positive (NCT06652139) | Ruijin Hospital | 2024-11-01 |
| Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion (NCT06739395) | Tianjin Medical University Second Hospital | 2024-11-01 |
| A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma (NCT06308575) | M.D. Anderson Cancer Center | 2024-11-01 |
| The Effects of Metformin on Morbidity and Mortality in Elderly Patients (NCT04530058) | Hamilton Health Sciences Corporation | 2024-11-01 |
| Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer (NCT07562659) | Fudan University | 2024-11-01 |
| Trial of Erythrocyte Encapsulated Thymidine Phosphorylase In Mitochondrial Neurogastrointestinal Encephalomyopathy (NCT03866954) | St George's, University of London | 2024-11-01 |
| Atorvaststin and Cardiotoxicity in Acute Myloid Leukemia (NCT06684509) | Assiut University | 2024-11-01 |
| To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma (NCT06702605) | Evopoint Biosciences Inc. | 2024-11-01 |